Gyre Therapeutics, Inc. Increase (Decrease) in Other Operating Assets
Gyre Therapeutics, Inc. (GYRE) reported Increase (Decrease) in Other Operating Assets of -$406.00 thousand for the 6-month period ending 2015-06-30, per its 10-Q filed 2015-07-31.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherOperatingAssets · last filed 2015-07-31
- Gyre Therapeutics, Inc. increase (decrease) in other operating assets for the quarter ending 2015-06-30 was -$112.00K, a 188.89% decline year-over-year.
- Gyre Therapeutics, Inc. increase (decrease) in other operating assets for the quarter ending 2015-03-31 was -$294.00K.
- Gyre Therapeutics, Inc. increase (decrease) in other operating assets for the quarter ending 2014-12-31 was -$421.00K.
- Gyre Therapeutics, Inc. increase (decrease) in other operating assets for the quarter ending 2014-09-30 was -$135.00K.
- Gyre Therapeutics, Inc. increase (decrease) in other operating assets for fiscal 2014 was -$565.00K.
- Gyre Therapeutics, Inc. increase (decrease) in other operating assets for fiscal 2013 was -$527.00K.
- Gyre Therapeutics, Inc. increase (decrease) in other operating assets for fiscal 2012 was -$2.02M.
| Period end | Increase (Decrease) in Other Operating Assets 3 month | Increase (Decrease) in Other Operating Assets 6 month | Increase (Decrease) in Other Operating Assets 9 month | Increase (Decrease) in Other Operating Assets 12 month |
|---|---|---|---|---|
| 2015-06-30 | -$112.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-07-31 | -$406.00K 10-Q · filed 2015-07-31 | -$827.00K derived: sum of 3 quarters · filed 2015-07-31 | -$962.00K derived: sum of 4 quarters · filed 2015-07-31 |
| 2015-03-31 | -$294.00K 10-Q · filed 2015-05-07 | -$715.00K derived: sum of 2 quarters · filed 2015-05-07 | -$850.00K derived: sum of 3 quarters · filed 2015-05-07 | -$724.00K derived: sum of 4 quarters · filed 2015-07-31 |
| 2014-12-31 | -$421.00K derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-16 | -$556.00K derived: sum of 2 quarters · filed 2015-03-16 | -$430.00K derived: sum of 3 quarters · filed 2015-07-31 | -$565.00K 10-K · filed 2015-03-16 |
| 2014-09-30 | -$135.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-06 | -$9.00K derived: sum of 2 quarters · filed 2015-07-31 | -$144.00K 10-Q · filed 2014-11-06 | -$543.00K derived: sum of 4 quarters · filed 2015-07-31 |
| 2014-06-30 | $126.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-07-31 | -$9.00K 10-Q · filed 2015-07-31 | -$408.00K derived: sum of 3 quarters · filed 2015-07-31 | -$948.00K derived: sum of 4 quarters · filed 2015-07-31 |
| 2014-03-31 | -$135.00K 10-Q · filed 2015-05-07 | -$534.00K derived: sum of 2 quarters · filed 2015-05-07 | -$1.07M derived: sum of 3 quarters · filed 2015-05-07 | -$803.00K derived: sum of 4 quarters · filed 2015-05-07 |
| 2013-12-31 | -$399.00K derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-16 | -$939.00K derived: sum of 2 quarters · filed 2015-03-16 | -$668.00K derived: sum of 3 quarters · filed 2015-03-16 | -$527.00K 10-K · filed 2015-03-16 |
| 2013-09-30 | -$540.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-06 | -$269.00K derived: sum of 2 quarters · filed 2014-11-06 | -$128.00K 10-Q · filed 2014-11-06 | |
| 2013-06-30 | $271.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-07 | $412.00K 10-Q · filed 2014-08-07 | ||
| 2013-03-31 | $141.00K 10-Q · filed 2014-05-08 | |||
| 2012-12-31 | -$2.02M 10-K · filed 2015-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |